hVIVO PLC (AIM:HVO) has signed its largest-ever human challenge trial contract, testing a whooping cough vaccine for US biotech ILiAD Biotechnologies. The trial will involve more than 500 volunteers and is expected to generate the majority of its revenue across 2026 and 2027. Watch more
Rift Helium PLC (AIM:RIFT) made a strong debut on AIM, with shares opening 10% above the 10p issue price after raising £8.1 million. The Tanzania-focused explorer is targeting a 19 billion cubic foot helium resource and plans to drill within the next 12 months. Read more
Galliford Try Holdings PLC (LSE:GFRD, FRA:3WC) has secured a place on a £750 million affordable homes framework with Sovereign Network Group across southern England. The win follows recent appointments to the Hyde Group framework and a new Clarion Housing contract. Read more
Valereum PLC (AQSE:VLRM, FRA:6TJ, OTCQB:VLRMF) has struck a definitive agreement with Quorium Global Photonics, replacing its existing notes with gold-backed tokens worth around $279.5 million. The deal is subject to verification of the underlying mining assets by an independent accounting firm. Read more
Accesso Technology Group PLC (LSE:ACSO, OTC:LOQPF, FRA:LQG) has appointed former Disney Parks executive Joni Newkirk to its board as a non-executive director. Her background in data analytics and revenue management across theme parks and hospitality is expected to support accesso's push into analytics-led growth. Read more
Solvonis Therapeutics PLC (LSE:SVNS) has hired US firm Water Tower Research to raise its profile with American investors. The CNS drug developer is targeting the US market as a key opportunity for its pipeline of treatments for alcohol use disorder, addiction and PTSD. Read more
Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.
